International expert consensus statement on the diagnosis and management of congenital nephrogenic diabetes insipidus (arginine vasopressin resistance).
Journal
Nature reviews. Nephrology
ISSN: 1759-507X
Titre abrégé: Nat Rev Nephrol
Pays: England
ID NLM: 101500081
Informations de publication
Date de publication:
22 Oct 2024
22 Oct 2024
Historique:
accepted:
13
09
2024
medline:
23
10
2024
pubmed:
23
10
2024
entrez:
22
10
2024
Statut:
aheadofprint
Résumé
Congenital nephrogenic diabetes insipidus (NDI; also known as arginine vasopressin resistance) is a rare inherited disorder of water homeostasis, caused by insensitivity of the distal nephron to arginine vasopressin. Consequently, the kidney loses its ability to concentrate urine, which leads to polyuria, polydipsia and the risk of hypertonic dehydration. The diagnosis and management of NDI are very challenging and require an integrated, multidisciplinary approach. Here, we present 36 recommendations for diagnosis, treatment and follow-up in both children and adults, as well as emergency management, genetic counselling and family planning, for patients with NDI. These recommendations were formulated and graded by an international group of experts in NDI from paediatric and adult nephrology, urology and clinical genetics from the European Rare Kidney Disease Reference Network and the European Society of Paediatric Nephrology, as well as patient advocates, and were validated by a voting panel in a Delphi process. The goal of these recommendations is to provide guidance to health care professionals who care for patients with NDI and to patients and their families. In addition, we emphasize the need for further research on different aspects of this potentially life-threatening disorder to support the development of evidence-based guidelines in the future.
Identifiants
pubmed: 39438674
doi: 10.1038/s41581-024-00897-z
pii: 10.1038/s41581-024-00897-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Nature Limited.
Références
Knoers, N. V. A. M., Levtchenko, E. & Bichet, D. G. In Pediatric Nephrology (eds Francesco, E. et al.) 1063–1085 (Springer International, 2022).
Arima, H. et al. Changing the name of diabetes insipidus: a position statement of the working group for renaming diabetes insipidus. J. Clin. Endocrinol. Metab. 108, 1–3 (2022).
pubmed: 36355385
pmcid: 9759163
doi: 10.1210/clinem/dgac547
Bockenhauer, D., Knoers, N. & Bichet, D. G. What’s in a name? That which we call diabetes does not taste sweet! Pediatr. Nephrol. 38, 937–939 (2023).
pubmed: 36369299
doi: 10.1007/s00467-022-05815-8
D’Alessandri-Silva, C. et al. Diagnosis, treatment, and outcomes in children with congenital nephrogenic diabetes insipidus: a pediatric nephrology research consortium study. Front. Pediatr. 7, 550 (2019).
pubmed: 32039113
doi: 10.3389/fped.2019.00550
Prosperi, F. et al. Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation. Sci. Rep. 10, 16383 (2020).
pubmed: 33009446
pmcid: 7532466
doi: 10.1038/s41598-020-73089-x
Bichet, D. G. & Bockenhauer, D. Genetic forms of nephrogenic diabetes insipidus (NDI): vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant). Best. Pract. Res. Clin. Endocrinol. Metab. 30, 263–276 (2016).
pubmed: 27156763
doi: 10.1016/j.beem.2016.02.010
Bockenhauer, D. & Bichet, D. G. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat. Rev. Nephrol. 11, 576–588 (2015).
pubmed: 26077742
doi: 10.1038/nrneph.2015.89
Chen, Y. et al. A reporting tool for practice guidelines in health care: the RIGHT Statement. Ann. Intern. Med. 166, 128–132 (2017).
pubmed: 27893062
doi: 10.7326/M16-1565
Guyatt, G. H. et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J. Clin. Epidemiol. 64, 395–400 (2011).
pubmed: 21194891
doi: 10.1016/j.jclinepi.2010.09.012
Management, A. A. O. P. S. C. O. Q. I. a. Classifying recommendations for clinical practice guidelines. Pediatrics 114, 874–877 (2004).
doi: 10.1542/peds.2004-1260
Flynn, J. T. et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140, e20171904 (2017).
pubmed: 28827377
doi: 10.1542/peds.2017-1904
Wesche, D., Deen, P. M. & Knoers, N. V. Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr. Nephrol. 27, 2183–2204 (2012).
pubmed: 22427315
doi: 10.1007/s00467-012-2118-8
Moeller, H. B., Rittig, S. & Fenton, R. A. Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. Endocr. Rev. 34, 278–301 (2013).
pubmed: 23360744
pmcid: 3610677
doi: 10.1210/er.2012-1044
Joshi, S. et al. Novel and recurrent variants in AVPR2 in 19 families with X-linked congenital nephrogenic diabetes insipidus. Eur. J. Pediatr. 177, 1399–1405 (2018).
pubmed: 29594432
doi: 10.1007/s00431-018-3132-z
Knoers, N. & Lemmink, H. Hereditary nephrogenic diabetes insipidus. in: M. P. Adam et al. (eds) GeneReviews(®) (University of Washington, Seattle Copyright © 1993–2023, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved., 1993) (2000, updated 2020).
Forssman, H. Is hereditary diabetes insipidus of nephrogenic type associated with mental deficiency? Acta Psychiatr. Neurol. Scand. 30, 577–587 (1955).
pubmed: 13301914
doi: 10.1111/j.1600-0447.1955.tb01010.x
Hoekstra, J. A., van Lieburg, A. F., Monnens, L. A., Hulstijn-Dirkmaat, G. M. & Knoers, V. V. Cognitive and psychosocial functioning of patients with congenital nephrogenic diabetes insipidus. Am. J. Med. Genet. 61, 81–88 (1996).
pubmed: 8741926
doi: 10.1002/(SICI)1096-8628(19960102)61:1<81::AID-AJMG17>3.0.CO;2-S
Bichet, D. G. Genetics in endocrinology pathophysiology, diagnosis and treatment of familial nephrogenic diabetes insipidus. Eur. J. Endocrinol. 183, R29–r40 (2020).
pubmed: 32580146
doi: 10.1530/EJE-20-0114
Hureaux, M. & Vargas-Poussou, R. Genetic basis of nephrogenic diabetes insipidus. Mol. Cell Endocrinol. 560, 111825 (2023).
pubmed: 36460218
doi: 10.1016/j.mce.2022.111825
Ishida, A. et al. Partial nephrogenic diabetes insipidus with a novel arginine vasopressin receptor 2 gene variant. Clin. Pediatr. Endocrinol. 31, 44–49 (2022).
pubmed: 35002068
doi: 10.1297/cpe.2021-0029
Arthus, M. F. et al. Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus. J. Am. Soc. Nephrol. 11, 1044–1054 (2000).
pubmed: 10820168
doi: 10.1681/ASN.V1161044
Moses, A. M., Sangani, G. & Miller, J. L. Proposed cause of marked vasopressin resistance in a female with an X-linked recessive V2 receptor abnormality. J. Clin. Endocrinol. Metab. 80, 1184–1186 (1995).
pubmed: 7714087
van Lieburg, A. F. et al. Clinical phenotype of nephrogenic diabetes insipidus in females heterozygous for a vasopressin type 2 receptor mutation. Hum. Genet. 96, 70–78 (1995).
pubmed: 7607658
doi: 10.1007/BF00214189
Migeon, B. R. X inactivation, female mosaicism, and sex differences in renal diseases. J. Am. Soc. Nephrol. 19, 2052–2059 (2008).
pubmed: 18448583
doi: 10.1681/ASN.2008020198
Satoh, M., Ogikubo, S. & Yoshizawa-Ogasawara, A. Correlation between clinical phenotypes and X-inactivation patterns in six female carriers with heterozygote vasopressin type 2 receptor gene mutations. Endocr. J. 55, 277–284 (2008).
pubmed: 18323675
doi: 10.1507/endocrj.K07-083
Morgenthaler, N. G., Struck, J., Alonso, C. & Bergmann, A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin. Chem. 52, 112–119 (2006).
pubmed: 16269513
doi: 10.1373/clinchem.2005.060038
Timper, K. et al. Diagnostic accuracy of copeptin in the differential diagnosis of the polyuria-polydipsia syndrome: a prospective multicenter study. J. Clin. Endocrinol. Metab. 100, 2268–2274 (2015).
pubmed: 25768671
doi: 10.1210/jc.2014-4507
Fenske, W. et al. A copeptin-based approach in the diagnosis of diabetes insipidus. N. Engl. J. Med. 379, 428–439 (2018).
pubmed: 30067922
doi: 10.1056/NEJMoa1803760
Christ-Crain, M. & Gaisl, O. Diabetes insipidus. Presse Med. 50, 104093 (2021).
pubmed: 34718110
doi: 10.1016/j.lpm.2021.104093
Winzeler, B. et al. Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. Lancet 394, 587–595 (2019).
pubmed: 31303316
doi: 10.1016/S0140-6736(19)31255-3
Refardt, J. et al. Arginine or hypertonic saline-stimulated copeptin to diagnose AVP deficiency. N. Engl. J. Med. 389, 1877–1887 (2023).
pubmed: 37966286
doi: 10.1056/NEJMoa2306263
Vergier, J. et al. Rapid differential diagnosis of diabetes insipidus in a 7-month-old infant: the copeptin approach. Arch. Pediatr. 25, 45–47 (2018).
pubmed: 29241593
doi: 10.1016/j.arcped.2017.11.010
Tuli, G., Tessaris, D., Einaudi, S., Matarazzo, P. & De Sanctis, L. Copeptin role in polyuria-polydipsia syndrome differential diagnosis and reference range in paediatric age. Clin. Endocrinol. 88, 873–879 (2018).
doi: 10.1111/cen.13583
Bitencourt, L. et al. The usefulness of copeptin for the diagnosis of nephrogenic diabetes insipidus in infancy: a case report. J. Pediatr. Endocrinol. Metab. 34, 1475–1479 (2021).
pubmed: 34291622
doi: 10.1515/jpem-2021-0296
Bonnet, L. et al. Copeptin assays in children for the differential diagnosis of polyuria-polydipsia syndrome and reference levels in hospitalized children. Clin. Endocrinol. 96, 47–53 (2022).
doi: 10.1111/cen.14620
Binder, G., Weber, K., Peter, A. & Schweizer, R. Arginine-stimulated copeptin in children and adolescents. Clin. Endocrinol. 98, 548–553 (2023).
doi: 10.1111/cen.14880
Monnens, L., Smulders, Y., van Lier, H. & de Boo, T. DDAVP test for assessment of renal concentrating capacity in infants and children. Nephron 29, 151–154 (1981).
pubmed: 7329489
doi: 10.1159/000182339
Bichet, D. G. Evaluation of Patients with Polyuria. http://www.uptodate.com (2023).
De Wardener, H. E. & Herxheimer, A. The effect of a high water intake on the kidney’s ability to concentrate the urine in man. J. Physiol. 139, 42–52 (1957).
pubmed: 13481895
pmcid: 1358676
doi: 10.1113/jphysiol.1957.sp005873
Verbalis, J. G. Whole-body volume regulation and escape from antidiuresis. Am. J. Med. 119, S21–S29 (2006).
pubmed: 16843081
doi: 10.1016/j.amjmed.2006.05.004
Moritz, M. L. & Ayus, J. C. Maintenance intravenous fluids in acutely Ill patients. N. Engl. J. Med. 373, 1350–1360 (2015).
pubmed: 26422725
doi: 10.1056/NEJMra1412877
Gennari, F. J. & Kassirer, J. P. Osmotic diuresis. N. Engl. J. Med. 291, 714–720 (1974).
pubmed: 4604866
doi: 10.1056/NEJM197410032911408
Bockenhauer, D. & Bichet, D. G. Nephrogenic diabetes insipidus. Curr. Opin. Pediatr. 29, 199–205 (2017).
pubmed: 28134709
doi: 10.1097/MOP.0000000000000473
Rees, L. et al. Delivery of a nutritional prescription by enteral tube feeding in children with chronic kidney disease stages 2–5 and on dialysis — clinical practice recommendations from the Pediatric Renal Nutrition Taskforce. Pediatr. Nephrol. 36, 187–204 (2021).
pubmed: 32728841
doi: 10.1007/s00467-020-04623-2
Lejarraga, H., Caletti, M. G., Caino, S. & Jiménez, A. Long-term growth of children with nephrogenic diabetes insipidus. Pediatr. Nephrol. 23, 2007–2012 (2008).
pubmed: 18584216
doi: 10.1007/s00467-008-0844-8
Sharma, S. et al. Long-term outcome in inherited nephrogenic diabetes insipidus. Clin. Kidney J. 12, 180–187 (2019).
pubmed: 30976394
doi: 10.1093/ckj/sfy027
Lopez-Garcia, S. C. et al. Treatment and long-term outcome in primary nephrogenic diabetes insipidus. Nephrol. Dial. Transpl. https://doi.org/10.1093/ndt/gfaa243 (2020).
doi: 10.1093/ndt/gfaa243
Qizalbash, L., Cleghorn, S., McAlister, L. in: V. Shaw (ed.) Clinical Paediatric Dietetics. 238 (Wiley-Blackwell 2020).
Sasaki, G. et al. Growth failure in an infant with congenital nephrogenic diabetes insipidus during sodium restriction. Clin. Pediatr. Endocrinol. 16, 95–98 (2007).
pubmed: 24790353
pmcid: 4004888
doi: 10.1297/cpe.16.95
Haycock, G. B. The influence of sodium on growth in infancy. Pediatr. Nephrol. 7, 871–875 (1993).
pubmed: 8130123
doi: 10.1007/BF01213376
Scientific advisory committee on nutrition. Salt and Health. (The Stationery Office, 2003).
Coleman, J. in: V. Shaw, Lawson, M. (eds) Clinical Paediatric Dietetics. 1324, (Blackwell Science Ltd, 2001).
Bockenhauer, D. & Bichet, D. G. Urinary concentration: different ways to open and close the tap. Pediatr. Nephrol. 29, 1297–1303 (2014).
pubmed: 23736674
doi: 10.1007/s00467-013-2526-4
Mortensen, L. A., Bistrup, C., Jensen, B. L. & Hinrichs, G. R. A mini-review of pharmacological strategies used to ameliorate polyuria associated with X-linked nephrogenic diabetes insipidus. Am. J. Physiol. Renal Physiol. 319, F746–F753 (2020).
pubmed: 32924547
doi: 10.1152/ajprenal.00339.2020
Earley, L. E. & Orloff, J. The mechanism of antidiuresis associated with the administration of hydrochlorothiazide to patients with vasopressin-resistant diabetes insipidus. J. Clin. Invest. 41, 1988–1997 (1962).
pubmed: 16695887
pmcid: 291129
doi: 10.1172/JCI104657
Anton-Gamero, M., Garcia-Martinez, E., Fernandez-Ramos, J., Rodríguez-Salas, M. & Gil-Campos, M. Nephrogenic diabetes insipidus: the key element of paradoxical hyponatremia. Pediatr. Nephrol. 24, 2277–2278 (2009).
pubmed: 19593589
doi: 10.1007/s00467-009-1236-4
Boussemart, T., Nsota, J., Martin-Coignard, D. & Champion, G. Nephrogenic diabetes insipidus: treat with caution. Pediatr. Nephrol. 24, 1761–1763 (2009).
pubmed: 19373493
doi: 10.1007/s00467-009-1187-9
Kirchlechner, V., Koller, D. Y., Seidl, R. & Waldhauser, F. Treatment of nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride. Arch. Dis. Child. 80, 548–552 (1999).
pubmed: 10332005
pmcid: 1717946
doi: 10.1136/adc.80.6.548
Wu, H. Y. Achieving urinary continence in children. Nat. Rev. Urol. 7, 371–377 (2010).
pubmed: 20531385
doi: 10.1038/nrurol.2010.78
Colliver, D., Storey, R., Dickens, H. & Subramaniam, R. Nonobstructive urinary tract dilatation in children with diabetes insipidus. J. Pediatr. Surg. 47, 752–755 (2012).
pubmed: 22498392
doi: 10.1016/j.jpedsurg.2011.08.007
Wang, X. et al. Upper urinary dilatation and treatment of 26 patients with diabetes insipidus: a single-center retrospective study. Front. Endocrinol. 13, 941453 (2022).
doi: 10.3389/fendo.2022.941453
Pedersen, S. A. et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark. J. Am. Acad. Dermatol. 78, 673–681.e679 (2018).
pubmed: 29217346
doi: 10.1016/j.jaad.2017.11.042
Alon, U. & Chan, J. C. Hydrochlorothiazide-amiloride in the treatment of congenital nephrogenic diabetes insipidus. Am. J. Nephrol. 5, 9–13 (1985).
pubmed: 3970081
doi: 10.1159/000166896
Konoshita, T. et al. Treatment of congenital nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride in an adult patient. Horm. Res. 61, 63–67 (2004).
pubmed: 14646392
Levin, A. et al. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 1–150 (2013).
Guarino, S. et al. Nephrogenic diabetes insipidus in childhood: assessment of volume status and appropriate fluid replenishment. Pediatr. Emerg. Care 36, e402–e404 (2020).
pubmed: 29489607
doi: 10.1097/PEC.0000000000001438
Holliday, M. A. & Segar, W. E. The maintenance need for water in parenteral fluid therapy. Pediatrics 19, 823–832 (1957).
pubmed: 13431307
doi: 10.1542/peds.19.5.823
National Institute for Health and Care Excellence. Intravenous fluid therapy in adults in hospital. Clinical guideline [CG174], http://www.nice.org.uk/Guidance/CG174 (2013, updated 2017).
Erdem Tuncdemir, B., Mergen, H. & Saglar Ozer, E. Evaluation of pharmacochaperone-mediated rescue of mutant V2 receptor proteins. Eur. J. Pharmacol. 865, 172803 (2019).
pubmed: 31738937
doi: 10.1016/j.ejphar.2019.172803
Morello, J. P. et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Invest. 105, 887–895 (2000).
pubmed: 10749568
pmcid: 377482
doi: 10.1172/JCI8688
Ranadive, S. A. et al. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus. Clin. Endocrinol. 71, 388–393 (2009).
doi: 10.1111/j.1365-2265.2008.03513.x
Robben, J. H., Sze, M., Knoers, N. V. & Deen, P. M. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. Am. J. Physiol. Renal Physiol. 292, F253–F260 (2007).
pubmed: 16926443
doi: 10.1152/ajprenal.00247.2006
Robben, J. H. et al. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proc. Natl Acad. Sci. USA 106, 12195–12200 (2009).
pubmed: 19587238
pmcid: 2715499
doi: 10.1073/pnas.0900130106
Bernier, V. et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J. Am. Soc. Nephrol. 17, 232–243 (2006).
pubmed: 16319185
doi: 10.1681/ASN.2005080854
Li, J. H. et al. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. J. Clin. Invest. 119, 3115–3126 (2009).
pubmed: 19729836
pmcid: 2752083
doi: 10.1172/JCI39680
Olesen, E. T., Rützler, M. R., Moeller, H. B., Praetorius, H. A. & Fenton, R. A. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus. Proc. Natl Acad. Sci. USA 108, 12949–12954 (2011).
pubmed: 21768374
pmcid: 3150913
doi: 10.1073/pnas.1104691108
Aihara, M. et al. Pharmacokinetics, safety, and intraocular pressure-lowering profile of omidenepag isopropyl, a selective, nonprostaglandin, prostanoid EP2 receptor agonist, in healthy Japanese and Caucasian volunteers (phase I study). J. Ocul. Pharmacol. Ther. 35, 542–550 (2019).
pubmed: 31674861
pmcid: 6918846
doi: 10.1089/jop.2019.0044
Steinwall, M., Akerlund, M., Bossmar, T., Nishii, M. & Wright, M. ONO-8815Ly, an EP2 agonist that markedly inhibits uterine contractions in women. BJOG 111, 120–124 (2004).
pubmed: 14723748
doi: 10.1046/j.1471-0528.2003.00016.x
Aihara, M. et al. Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective EP2 agonist, in patients with primary open-angle glaucoma or ocular hypertension. J. Glaucoma 28, 375–385 (2019).
pubmed: 30839416
doi: 10.1097/IJG.0000000000001221
Boone, M., Kortenoeven, M., Robben, J. H. & Deen, P. M. Effect of the cGMP pathway on AQP2 expression and translocation: potential implications for nephrogenic diabetes insipidus. Nephrol. Dial. Transpl. 25, 48–54 (2010).
doi: 10.1093/ndt/gfp409
Bouley, R. et al. Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin 2 in renal epithelial cells. J. Clin. Invest. 106, 1115–1126 (2000).
pubmed: 11067864
pmcid: 301414
doi: 10.1172/JCI9594
Bouley, R. et al. Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra). Am. J. Physiol. Renal Physiol. 288, F1103–F1112 (2005).
pubmed: 15644488
doi: 10.1152/ajprenal.00337.2004
Hinrichs, G. R. et al. Treatment of nephrogenic diabetes insipidus patients with cGMP-stimulating drugs does not mitigate polyuria or increase urinary concentrating ability. Kidney Int. Rep. 5, 1319–1325 (2020).
pubmed: 32775834
pmcid: 7403538
doi: 10.1016/j.ekir.2020.05.015
ClinicalTrials.gov. US National Library of Medicine. https://clinicaltrials.gov/study/NCT02460354 (2018).
Klein, J. D. et al. An AMPK activator as a therapeutic option for congenital nephrogenic diabetes insipidus. JCI Insight 6, e146419 (2021).
pubmed: 33724959
pmcid: 8119225
doi: 10.1172/jci.insight.146419
Sohara, E. et al. Pathogenesis and treatment of autosomal-dominant nephrogenic diabetes insipidus caused by an aquaporin 2 mutation. Proc. Natl Acad. Sci. USA 103, 14217–14222 (2006).
pubmed: 16968783
pmcid: 1599937
doi: 10.1073/pnas.0602331103
Bichet, D. G., Ruel, N., Arthus, M. F. & Lonergan, M. Rolipram, a phosphodiesterase inhibitor, in the treatment of two male patients with congenital nephrogenic diabetes insipidus. Nephron 56, 449–450 (1990).
pubmed: 1964202
doi: 10.1159/000186196
Vukićević, T. et al. Fluconazole increases osmotic water transport in renal collecting duct through effects on aquaporin-2 trafficking. J. Am. Soc. Nephrol. 30, 795–810 (2019).
pubmed: 30988011
pmcid: 6493977
doi: 10.1681/ASN.2018060668
Treatment of congenital nephrogenic diabetes insipidus with fluconazole, an antifungal medication. https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002204-38/DK .
Davis, L. & Park, F. Gene therapy research for kidney diseases. Physiol. Genomics 51, 449–461 (2019).
pubmed: 31398086
doi: 10.1152/physiolgenomics.00052.2019
Bockenhauer, D. & Bichet, D. G. Inherited secondary nephrogenic diabetes insipidus: concentrating on humans. Am. J. Physiol. Renal Physiol. 304, F1037–F1042 (2013).
pubmed: 23364801
doi: 10.1152/ajprenal.00639.2012
Hudson, J. L., Baum, J. I., Diaz, E. C. & Børsheim, E. Dietary protein requirements in children: methods for consideration. Nutrients 13, 1554 (2021).
pubmed: 34063030
pmcid: 8147948
doi: 10.3390/nu13051554
Richter, M. et al. Revised reference values for the intake of protein. Ann. Nutr. Metab. 74, 242–250 (2019).
pubmed: 30904906
doi: 10.1159/000499374
Crawford, J. D. & Kennedy, G. C. Chlorothiazid in diabetes insipidus. Nature 183, 891–892 (1959).
pubmed: 13644230
doi: 10.1038/183891a0
Kennedy, G. C. & Crawford, J. D. Treatment of diabetes insipidus with hydrochlorothiazide. Lancet 1, 866–867 (1959).
pubmed: 13655610
doi: 10.1016/S0140-6736(59)91943-9
Knoers, N. & Monnens, L. A. Amiloride-hydrochlorothiazide versus indomethacin-hydrochlorothiazide in the treatment of nephrogenic diabetes insipidus. J. Pediatr. 117, 499–502 (1990).
pubmed: 2391611
doi: 10.1016/S0022-3476(05)81106-0
Gambaro, G. & Perazella, M. A. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J. Intern. Med. 253, 643–652 (2003).
pubmed: 12755960
doi: 10.1046/j.1365-2796.2003.01146.x
Jakobsson, B. & Berg, U. Effect of hydrochlorothiazide and indomethacin treatment on renal function in nephrogenic diabetes insipidus. Acta Paediatr. 83, 522–525 (1994).
pubmed: 8086732
doi: 10.1111/j.1651-2227.1994.tb13072.x
Monnens, L., Jonkman, A. & Thomas, C. Response to indomethacin and hydrochlorothiazide in nephrogenic diabetes insipidus. Clin. Sci. 66, 709–715 (1984).
doi: 10.1042/cs0660709
Rascher, W., Rosendahl, W., Henrichs, I. A., Maier, R. & Seyberth, H. W. Congenital nephrogenic diabetes insipidus-vasopressin and prostaglandins in response to treatment with hydrochlorothiazide and indomethacin. Pediatr. Nephrol. 1, 485–490 (1987).
pubmed: 3153321
doi: 10.1007/BF00849258
Harris, R. C. Jr Cyclooxygenase-2 inhibition and renal physiology. Am. J. Cardiol. 89, 10d–17d (2002).
pubmed: 11909556
doi: 10.1016/S0002-9149(02)02232-4
Libber, S., Harrison, H. & Spector, D. Treatment of nephrogenic diabetes insipidus with prostaglandin synthesis inhibitors. J. Pediatr. 108, 305–311 (1986).
pubmed: 3080575
doi: 10.1016/S0022-3476(86)81010-1
Pattaragarn, A. & Alon, U. S. Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor. Pediatr. Nephrol. 18, 1073–1076 (2003).
pubmed: 12883974
doi: 10.1007/s00467-003-1195-0